Developer docs
API playgroundTry for free, no card

Search company profiles

Enterprise Therapeutics

Full company profile

uuid00027wp

Namestring
Enterprise Therapeutics
Legal namestring
Enterprise Therapeutics Limited
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Enterprise Therapeutics is a UK-based clinical-stage biopharmaceutical company founded in 2014 that develops muco-regulatory therapies targeting the underlying mechanisms of mucus congestion in respiratory diseases. The company's lead programs target two ion channels — ENaC and TMEM16A — to restore airway hydration and mucus clearance in cystic fibrosis (CF), COPD, severe asthma, and non-CF bronchiectasis. Its core asset, ETD001, is a novel inhaled ENaC blocker that in May 2026 became the first investigational ENaC blocker to deliver clinically relevant and statistically significant improvement in lung function in a Phase 2 trial (3.4 percentage point improvement in ppFEV1, p=0.0053). A second program, ETD002 (first-in-class TMEM16A potentiator), was fully divested to Roche in October 2020 for £75 million upfront plus contingent milestones. Drug discovery is supported by the company's proprietary Bronchosphere platform, a miniaturized human airway model used for high-throughput target identification and compound screening, with medicinal chemistry collaboration through Evotec and academic partnerships with the University of Sussex, UNC, and University of Miami.

The company generates revenue through pharmaceutical licensing, partnership divestitures, and non-dilutive grant funding rather than direct product sales. The £75 million upfront from Roche for the TMEM16A portfolio in 2020 is the only material disclosed commercial transaction, supplemented by a £7 million Cystic Fibrosis Foundation Therapeutics Development Award and a Cystic Fibrosis Trust grant for bronchosphere research. Enterprise's go-to-market approach targets regulatory engagement (FDA Rare Pediatric Disease Designation for ETD001 granted September 2024, EMA interactions), clinical investigator networks across the UK, Germany, France, and Italy, and scientific communications through peer-reviewed publications in The Journal of Cystic Fibrosis, European Journal of Medicinal Chemistry, and American Journal of Respiratory and Critical Care Medicine, plus presentations at NACFC, ECFS, and Gordon Research Conferences. The company has raised approximately £62 million in equity from a syndicate of specialist life-sciences investors including Epidarex Capital, Versant Ventures, Novartis Venture Fund, Forbion, IP Group, and Panakes Partners, and operates a wholly-owned Italian subsidiary (Enterprise Therapeutics S.R.L.) to support R&D and clinical operations across Europe.

Short descriptiontext

Enterprise Therapeutics is a UK-based clinical-stage biopharmaceutical company developing novel muco-regulatory therapies (ENaC blockers and TMEM16A potentiators) for cystic fibrosis, COPD, severe asthma, and non-CF bronchiectasis, with lead asset ETD001 having achieved positive Phase 2 results in 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFalmer, United Kingdom
HQ citystring
Falmer
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory disease therapeutics, cystic fibrosis treatments, muco-regulatory drug discovery, inhaled ENaC blockers, ion channel modulators
Industry2 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Respiratory Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue clinical stage biopharmaceutical company. The company develops novel therapies through clinical trials with the intent to commercialize or license. TMEM16A potentiator programme (ETD002) was acquired by Roche for £75 million upfront with additional milestone payments.

enterprisetherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing novel muco-regulatory therapies that target ion channels (ENaC and TMEM16A) to restore airway mucus hydration and clearance in respiratory diseases. Its lead asset, ETD001, is a first-in-class inhaled ENaC blocker for cystic fibrosis that achieved positive Phase 2 results. The company also operates the Bronchosphere technology platform, a miniaturized model of the human airway used for high-throughput drug and target discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 3.4% points improvement in ppFEV1 (p=0.0053) compared to placebo in 28-day Phase 2 trial
+3 more records
Product overview1 text field

Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing muco-regulatory therapies for respiratory diseases. The company's portfolio includes ETD001, a novel inhaled ENaC blocker that achieved positive Phase 2 results for cystic fibrosis, and the Bronchosphere platform technology for drug discovery. The TMEM16A potentiator programme (ETD002) was acquired by Roche. The company targets underlying mechanisms of mucus congestion through ion channel modulation to enhance clearance and restore lung function in CF, COPD, and severe asthma.

Product and service1 record
1ETD001
CategoryInvestigational inhaled ENaC blocker (cystic fibrosis)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-19
Description

Medicinal chemistry work described in European Journal of Medicinal Chemistry publication was carried out in collaboration with Evotec, supporting optimization of ENaC blocker compounds leading to ETD001.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-07
Description

Roche fully acquired Enterprise's TMEM16A potentiator portfolio, to be developed by Genentech. Enterprise received £75 million upfront payment with eligibility for additional contingent milestone payments. Portfolio included ETD002, a first-in-class TMEM16A potentiator in Phase 1.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-08
Description

Enterprise has close working relationship with School of Life Sciences at University of Sussex. Collaborated on TMEM16A research published in American Journal of Respiratory and Critical Care Medicine along with Sussex Drug Discovery Centre researchers.

Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2020-01-08
Description

Research collaboration with Brian Button from UNC Chapel Hill on TMEM16A potentiator programme and mucus clearance research.

Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2020-01-08
Description

Research collaboration with Juan Sabater from Mount Sinai Medical Center, University of Miami on TMEM16A research.

Strategic tierMinorTypeOthers
Description

Enterprise Therapeutics Ltd's EU Representative is The DPO Centre, based in Paris, France, providing data protection officer services for EU compliance.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vertex is the dominant cystic fibrosis franchise holder with Trikafta/Kaftrio and other CFTR modulators treating ~90% of CF patients. Enterprise's ETD001 targets the residual CF population not benefiting from Vertex's therapies, making Vertex the most direct competitive benchmark.

TypeEmerging player
Description

Arcturus is developing CFTR mRNA therapeutics (ARCT-032) for cystic fibrosis, targeting patients not responsive to modulators. Overlaps with Enterprise's addressable patient population through a different therapeutic modality (mRNA vs. ENaC inhibition).

TypeDirect peer
Description

Galapagos has historically been active in cystic fibrosis drug development with CFTR modulators and has broader respiratory pipeline interest. Dr Niyati Prasad, Enterprise's CMO, previously held leadership roles at Galapagos.

4TFF Pharmaceuticals
TypeEmerging player
Description

TFF Pharmaceuticals develops inhaled drug formulations for respiratory diseases including CF using thin-film freezing technology. Overlaps with Enterprise's inhaled delivery approach for respiratory therapeutics targeting mucus-related diseases.

TypeBroad incumbent
Description

AbbVie has a major respiratory franchise including therapies for asthma and COPD. Dr Janet Hammond, Enterprise's NED, was previously VP and Head of Infectious Diseases and General Medicine at AbbVie, indicating close familiarity.

TypeEmerging player
Description

4DMT is developing aerosolized gene therapies for cystic fibrosis lung disease, targeting the same CF population underserved by modulators. Represents an emerging modality-based competitor in the residual CF segment.

TypeDirect peer
Description

Parion developed epithelial sodium channel (ENaC) blockers for respiratory diseases and was acquired by Vertex. Direct mechanistic overlap with Enterprise's ETD001 (also an ENaC inhibitor) makes Parion a precedent competitor in the same pharmacological class.

TypeEmerging player
Description

Eloxx has been developing therapies for rare CF mutations including nonsense mutations, partially overlapping with Enterprise's addressable population in CF. Both target patients with limited or no therapeutic options.

TypeDirect peer
Description

Insmed develops respiratory therapeutics, notably brensocatib for non-CF bronchiectasis, an indication Enterprise plans to enter. Both companies target mucus-related and chronic respiratory diseases with late-stage clinical assets.

TypeBroad incumbent
Description

Roche acquired Enterprise's TMEM16A potentiator portfolio for £75M upfront. As the developer of the divested ETD002 program and a global pharma leader with respiratory interests, Roche is both a historical partner and a potential acquirer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enterprise Therapeutics

Respiratory Pharmaceuticalsenterprisetherapeutics.com

Enterprise Therapeutics is a UK-based clinical-stage biopharmaceutical company developing novel muco-regulatory therapies (ENaC blockers and TMEM16A potentiators) for cystic fibrosis, COPD, severe asthma, and non-CF bronchiectasis, with lead asset ETD001 having achieved positive Phase 2 results in 2026.

What Enterprise Therapeutics does

Enterprise Therapeutics is a UK-based clinical-stage biopharmaceutical company founded in 2014 that develops muco-regulatory therapies targeting the underlying mechanisms of mucus congestion in respiratory diseases. The company's lead programs target two ion channels — ENaC and TMEM16A — to restore airway hydration and mucus clearance in cystic fibrosis (CF), COPD, severe asthma, and non-CF bronchiectasis. Its core asset, ETD001, is a novel inhaled ENaC blocker that in May 2026 became the first investigational ENaC blocker to deliver clinically relevant and statistically significant improvement in lung function in a Phase 2 trial (3.4 percentage point improvement in ppFEV1, p=0.0053). A second program, ETD002 (first-in-class TMEM16A potentiator), was fully divested to Roche in October 2020 for £75 million upfront plus contingent milestones. Drug discovery is supported by the company's proprietary Bronchosphere platform, a miniaturized human airway model used for high-throughput target identification and compound screening, with medicinal chemistry collaboration through Evotec and academic partnerships with the University of Sussex, UNC, and University of Miami.

The company generates revenue through pharmaceutical licensing, partnership divestitures, and non-dilutive grant funding rather than direct product sales. The £75 million upfront from Roche for the TMEM16A portfolio in 2020 is the only material disclosed commercial transaction, supplemented by a £7 million Cystic Fibrosis Foundation Therapeutics Development Award and a Cystic Fibrosis Trust grant for bronchosphere research. Enterprise's go-to-market approach targets regulatory engagement (FDA Rare Pediatric Disease Designation for ETD001 granted September 2024, EMA interactions), clinical investigator networks across the UK, Germany, France, and Italy, and scientific communications through peer-reviewed publications in The Journal of Cystic Fibrosis, European Journal of Medicinal Chemistry, and American Journal of Respiratory and Critical Care Medicine, plus presentations at NACFC, ECFS, and Gordon Research Conferences. The company has raised approximately £62 million in equity from a syndicate of specialist life-sciences investors including Epidarex Capital, Versant Ventures, Novartis Venture Fund, Forbion, IP Group, and Panakes Partners, and operates a wholly-owned Italian subsidiary (Enterprise Therapeutics S.R.L.) to support R&D and clinical operations across Europe.

Enterprise Therapeutics firmographics

Firmographics
Name
Enterprise Therapeutics
Legal name
Enterprise Therapeutics Limited
Website
https://enterprisetherapeutics.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Enterprise Therapeutics is a UK-based clinical-stage biopharmaceutical company developing novel muco-regulatory therapies (ENaC blockers and TMEM16A potentiators) for cystic fibrosis, COPD, severe asthma, and non-CF bronchiectasis, with lead asset ETD001 having achieved positive Phase 2 results in 2026.
Ownership category
akta.pro rank

Enterprise Therapeutics industry classification

Industry
Product category
Respiratory Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Respiratory disease therapeutics
  • Cystic fibrosis treatments
  • Muco-regulatory drug discovery
  • Inhaled ENaC blockers
  • Ion channel modulators

Where Enterprise Therapeutics is headquartered

Location

Headquarters

HQ city
Falmer
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Enterprise Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Licensing: Pre-revenue clinical stage biopharmaceutical company. The company develops novel therapies through clinical trials with the intent to commercialize or license. TMEM16A potentiator programme (ETD002) was acquired by Roche for £75 million upfront with additional milestone payments.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Enterprise Therapeutics product offering

Product offering

Core offering

Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing novel muco-regulatory therapies that target ion channels (ENaC and TMEM16A) to restore airway mucus hydration and clearance in respiratory diseases. Its lead asset, ETD001, is a first-in-class inhaled ENaC blocker for cystic fibrosis that achieved positive Phase 2 results. The company also operates the Bronchosphere technology platform, a miniaturized model of the human airway used for high-throughput drug and target discovery.

Product overview

Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing muco-regulatory therapies for respiratory diseases. The company's portfolio includes ETD001, a novel inhaled ENaC blocker that achieved positive Phase 2 results for cystic fibrosis, and the Bronchosphere platform technology for drug discovery. The TMEM16A potentiator programme (ETD002) was acquired by Roche. The company targets underlying mechanisms of mucus congestion through ion channel modulation to enhance clearance and restore lung function in CF, COPD, and severe asthma.

Differentiator

Problem solved

Functional benefit

Products and services

  • ETD001

Quantifiable outcome

  • 3.4% points improvement in ppFEV1 (p=0.0053) compared to placebo in 28-day Phase 2 trial
  • +3 more outcomes

Companies that use Enterprise Therapeutics

Customer profile

Segments4 records

Ideal customer profiles3 records

Enterprise Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Enterprise Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, moderate and minor.

  • EvoteccoreStrategic or Co-development Partner · 19 November 2024Medicinal chemistry work described in European Journal of Medicinal Chemistry publication was carried out in collaboration with Evotec, supporting optimization of ENaC blocker compounds leading to ETD001.
  • Roche/GenentechcoreStrategic or Co-development Partner · 7 October 2020Roche fully acquired Enterprise's TMEM16A potentiator portfolio, to be developed by Genentech. Enterprise received £75 million upfront payment with eligibility for additional contingent milestone payments. Portfolio included ETD002, a first-in-class TMEM16A potentiator in Phase 1.
  • University of SussexcoreStrategic or Co-development Partner · 8 January 2020Enterprise has close working relationship with School of Life Sciences at University of Sussex. Collaborated on TMEM16A research published in American Journal of Respiratory and Critical Care Medicine along with Sussex Drug Discovery Centre researchers.
  • University of North CarolinamoderateStrategic or Co-development Partner · 8 January 2020Research collaboration with Brian Button from UNC Chapel Hill on TMEM16A potentiator programme and mucus clearance research.
  • University of MiamimoderateStrategic or Co-development Partner · 8 January 2020Research collaboration with Juan Sabater from Mount Sinai Medical Center, University of Miami on TMEM16A research.
  • The DPO CentreminorOthersEnterprise Therapeutics Ltd's EU Representative is The DPO Centre, based in Paris, France, providing data protection officer services for EU compliance.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Enterprise Therapeutics competitors and assessment

Company assessment

Direct peers

  • Vertex Pharmaceuticals: Vertex is the dominant cystic fibrosis franchise holder with Trikafta/Kaftrio and other CFTR modulators treating ~90% of CF patients. Enterprise's ETD001 targets the residual CF population not benefiting from Vertex's therapies, making Vertex the most direct competitive benchmark.
  • Galapagos NV: Galapagos has historically been active in cystic fibrosis drug development with CFTR modulators and has broader respiratory pipeline interest. Dr Niyati Prasad, Enterprise's CMO, previously held leadership roles at Galapagos.
  • Parion Sciences: Parion developed epithelial sodium channel (ENaC) blockers for respiratory diseases and was acquired by Vertex. Direct mechanistic overlap with Enterprise's ETD001 (also an ENaC inhibitor) makes Parion a precedent competitor in the same pharmacological class.
  • Insmed: Insmed develops respiratory therapeutics, notably brensocatib for non-CF bronchiectasis, an indication Enterprise plans to enter. Both companies target mucus-related and chronic respiratory diseases with late-stage clinical assets.

Emerging players

  • Arcturus Therapeutics: Arcturus is developing CFTR mRNA therapeutics (ARCT-032) for cystic fibrosis, targeting patients not responsive to modulators. Overlaps with Enterprise's addressable patient population through a different therapeutic modality (mRNA vs. ENaC inhibition).
  • TFF Pharmaceuticals: TFF Pharmaceuticals develops inhaled drug formulations for respiratory diseases including CF using thin-film freezing technology. Overlaps with Enterprise's inhaled delivery approach for respiratory therapeutics targeting mucus-related diseases.
  • 4D Molecular Therapeutics: 4DMT is developing aerosolized gene therapies for cystic fibrosis lung disease, targeting the same CF population underserved by modulators. Represents an emerging modality-based competitor in the residual CF segment.
  • Eloxx Pharmaceuticals: Eloxx has been developing therapies for rare CF mutations including nonsense mutations, partially overlapping with Enterprise's addressable population in CF. Both target patients with limited or no therapeutic options.

Broad incumbents

  • AbbVie: AbbVie has a major respiratory franchise including therapies for asthma and COPD. Dr Janet Hammond, Enterprise's NED, was previously VP and Head of Infectious Diseases and General Medicine at AbbVie, indicating close familiarity.
  • Roche/Genentech: Roche acquired Enterprise's TMEM16A potentiator portfolio for £75M upfront. As the developer of the divested ETD002 program and a global pharma leader with respiratory interests, Roche is both a historical partner and a potential acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Enterprise Therapeutics social profiles

Digital presence

Enterprise Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enterprise Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Enterprise Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Enterprise Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enterprise Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enterprise Therapeutics

What does Enterprise Therapeutics do?

Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing novel muco-regulatory therapies that target ion channels (ENaC and TMEM16A) to restore airway mucus hydration and clearance in respiratory diseases. Its lead asset, ETD001, is a first-in-class inhaled ENaC blocker for cystic fibrosis that achieved positive Phase 2 results. The company also operates the Bronchosphere technology platform, a miniaturized model of the human airway used for high-throughput drug and target discovery.

Is Enterprise Therapeutics a public or private company?

Enterprise Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Enterprise Therapeutics founded?

Enterprise Therapeutics was founded in 2014. It employs 11 to 50 people.

Where is Enterprise Therapeutics based?

Enterprise Therapeutics is headquartered in Falmer, United Kingdom, in the Europe region.

How does Enterprise Therapeutics make money?

One revenue line is on record: pharmaceutical Development and Licensing.

Who are Enterprise Therapeutics's main competitors?

Direct peers on record are Vertex Pharmaceuticals, Galapagos NV, Parion Sciences and Insmed. Emerging players are Arcturus Therapeutics, TFF Pharmaceuticals, 4D Molecular Therapeutics and Eloxx Pharmaceuticals. Broad incumbents are AbbVie and Roche/Genentech.

Does Enterprise Therapeutics have an API?

No public API is recorded for Enterprise Therapeutics.

What industry is Enterprise Therapeutics in?

Enterprise Therapeutics's product category is Respiratory Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalEnterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001The European Medicines Agency granted orphan medicinal product designation to Enterprise Therapeutics' ETD001, an inhaled ENaC blocker for cystic fibrosis. The decision follows a positive Phase 2 trial and offers market exclusivity. The company plans to continue development for cystic fibrosis and other mucus congestion-related respiratory diseases.FinancialContent Business PageEnterprise Therapeutics Granted EMA Orphan Medicinal Product Designation for Novel Cystic Fibrosis Therapy, ETD001The European Medicines Agency granted orphan medicinal product designation to ETD001, an inhaled ENaC blocker for cystic fibrosis, following a positive Phase 2 trial. The decision recognizes the drug's potential for patients not eligible for CFTR modulators and offers market exclusivity.PharmaTimesEnterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosisEnterprise Therapeutics reported positive phase 2 data for ETD001, an inhaled ENaC blocker, in cystic fibrosis patients not benefiting from CFTR modulators. The trial showed a 3.4% point improvement in ppFEV1 over 28 days versus placebo (p=0.0053). The company plans longer phase 2b studies and explores ETD001 in non-CF bronchiectasis.BioSpaceEnterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With Novel Inhaled ENaC Blocker ETD001Enterprise Therapeutics reported that its Phase 2 trial of inhaled ENaC blocker ETD001 achieved primary efficacy in cystic fibrosis patients, showing a 3.4% improvement in ppFEV1 versus placebo over 28 days. The trial was well-tolerated, and results will be presented at the European Cystic Fibrosis Society conference in Lisbon in June.Business Wire BlogEnterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With Novel Inhaled ENaC Blocker ETD001Enterprise Therapeutics reported positive primary efficacy results from its Phase 2 trial of inhaled ETD001 in cystic fibrosis patients not on CFTR modulators. The trial showed a 3.4% improvement in ppFEV1 versus placebo over 28 days, with a threefold higher likelihood of improvement. The company plans longer Phase 2b trials and a trial in non-CF bronchiectasis.News-MedicalEnterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001Enterprise Therapeutics reported positive primary efficacy results from its Phase 2 trial of inhaled ETD001 in cystic fibrosis patients not on CFTR modulators. The trial showed a 3.4% improvement in ppFEV1 over 28 days versus placebo (p=0.0053). The company plans longer Phase 2b trials and a trial in non-CF bronchiectasis.PharmaTimesEnterprise Therapeutics publishes results of phase 1 study of ETD001Enterprise Therapeutics announced the publication of results from its phase 1 study of ETD001, a long-acting inhaled ENaC blocker for cystic fibrosis, demonstrating that the treatment was well tolerated in healthy individuals at therapeutic doses. The phase 2 trial is now underway to assess whether 28 days of treatment can improve lung function in cystic fibrosis patients, with headline data expected in early 2026. Results showed a favourable safety profile with slow lung absorption and no impact on blood potassium levels, addressing key historical concerns with ENaC blockers.STATUp and down the ladder: The latest comings and goingsEnterprise Therapeutics hired Renu Gupta as chief medical officer, previously a consulting chief medical officer at Adiso Therapeutics. The company's regular feature highlights her appointment.Pulse 2.0Enterprise Therapeutics: £26 Million Series B Follow-On Financing RaisedEnterprise Therapeutics closed a £26 million Series B follow-on financing round led by Panakes Partners, with existing investors participating. The funds will support the Phase 2a clinical trial of its lead program ETD001 for cystic fibrosis, targeting the ENaC ion channel. The company also plans to expand clinical activities into Italy.News-MedicalEnterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financingEnterprise Therapeutics closed a £26 million ($33.1 million) Series B follow-on financing round led by Panakes Partners, with participation from existing investors. The funds will support the Phase 2a clinical trial of its lead programme ETD001 for cystic fibrosis, targeting the ENaC ion channel to improve mucus clearance and lung function.